Combination of oxaliplatin and irinotecan on human colon cancer cell lines: Activity in vitro and in vivo

Anti-Cancer Drugs

Volumn 12, Issue 9, 2001, Pages 741-751

  Guichard, Sylvie ^a   Arnould, Stéphanie ^a,b   Hennebelle, Isabelle ^a   Bugat, Roland ^a,b   Canal, Pierre ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Apoptosis; ERCC1; Human colon cancer cell lines; Irinotecan; Nucleotide excision repair; Oxaliplatin; Poly(ADP ribose) polymerase; Synergism; XPA

Indexed keywords

DNA; DNA TOPOISOMERASE; IRINOTECAN; OXALIPLATIN; PLATINUM;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DRUG POTENTIATION; ENZYME ACTIVITY; EXCISION REPAIR; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; COLONIC NEOPLASMS; DNA ADDUCTS; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; DRUG INTERACTIONS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENDONUCLEASES; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; ORGANOPLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 0034773290     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200110000-00006     Document Type: Article

References (29)

1. Oxaliplatin: A review of preclinical and clinical studies
2. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen
3. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers
4. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
5. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
6. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells
7. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro
8. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin
9. Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line
10. In vivo evaluation of the irinotecan-oxaliplatin combination
11. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin
12. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
13. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells
14. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy
15. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: A potential surrogate end point to assess treatment effectiveness
16. New colorimetric cytotoxicity assay for anticancer-drug screening
17. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
18. 50, LD50, synergism, low-dose risk, receptor-ligand binding and enzyme kinetics
19. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line
20. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
21. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin
22. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
23. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo
24. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
25. Inhibition of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells
26. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts
27. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues
28. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53
29. Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients